Russia plans for drugs against rare diseases

6 October 2022

The Russian government plans to speed up the development and production of domestic drugs against rare diseases amid the ever tightening pressure caused by sanctions on the country due to its military conflict with Ukraine.

So far, the Ministry of Health and the Ministry of Industry and Trade have already instructed domestic enterprises and pharmaceutical companies to quickly develop Russian analogues of 189 foreign drugs, a significant part of which will account for those drugs intended for the treatment of rare diseases.

As part of state plans, the production of most of these drugs should be launched in Russia by 2024. At the same time, as part of the existing “Patents on the Shelf” state program, the work is currently underway to develop drugs that are still protected by foreign patents and cannot be produced in Russia without the permission of the right holders. In addition, measures are being taken to create domestic production of pharmaceutical active ingredients that are not currently made in Russia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK